Home/ Stocks/ LITS

Lite Strategy, Inc. Common Stock

LITS XNAS

$1.24 -0.06 (-5.00%) ▼ 15-min delayed

Open

$1.28

High

$1.31

Low

$1.23

Volume

306.9K

Market Cap

$44.23M

About Lite Strategy, Inc. Common Stock

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 4 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$54.0K	$-23,694,000	$-0.66
Q2 2026	$60.0K	$-30,799,000	$-0.82
Q1 2026	$0	$-3,639,000	$-0.12

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 12, 2026

Calendar →

Related Market News

No specific coverage for LITS yet. Check out our latest market news or earnings calendar.

Get LITS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Lite Strategy, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.